drugset / Trial / NCT02951780

A Study of LY3185643 and rGlucagon in Healthy Participants

NCT02951780

Phase 1 Completed 23 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to determine how the body handles LY3185643 and rGlucagon and what effects LY3185643 and rGlucagon have on the body. This study will also help to determine if LY3185643 is safe and well-tolerated. This study will last at least 35 days, not including screening.

Timeline

Start
2016-11-01
Primary completion
2017-01-24
Completion
2017-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3185643 Unknown Subcutaneous
Subject rGlucagon Unknown Subcutaneous

Indications

No indication recorded.